Skip to main content
OpenTrials
Completed

NCT Number: NCT02287285

Determinants of Diabetes Remission After Gastric Bypass Surgery

Longitudinal study of beta cell function up to 2 years after GBP surgery. Evaluation of the role of endogenous glucagon-like peptide-1 (GLP-1).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

New York Obesity Research Center, Columbia University

New York, 10032, United States

About this study

The increased prevalence of obesity and type 2 diabetes (T2DM) has resulted in a surge in the number of patients seeking surgical weight loss. Gastric bypass surgery (GBP) results in 30-40% body weight loss with resolution of T2DM in 40-80% of cases. The mechanisms by which T2DM improves after GBP are unclear. Glycemic control occurs long before significant weight loss, suggesting that the nature of the procedure, rather than the weight loss, is responsible for the T2DM improvement. Recent data have singled out the role of the gut hormones known as incretins in diabetes improvement after GBP. The current proposal will study 1) whether the short and long term change in the gut hormone incretins after GBP results in improved insulin secretion in response to the administration of oral and IV glucose, in patients with diabetes undergoing GBP surgery; 2) the factors responsible for diabetes remission - or lack of - after GBP. The investigators wish to apply our finding to define better surgical outcome on diabetes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a wide range of T2DM (duration, treatment modalities and control, in or not in remission) and scheduled for GBP surgery
  • Blood pressure is under at least moderate control <160/100 mmHg
  • Patients can be on dyslipidemia medications but need fasting triglyceride < 600 mg/dl
  • Patients without recent (last 6 months) history of cardiovascular disease (CVD)
  • BMI > 35 and < 55 kg/m2 prior to GBP surgery

Exclusion criteria

  • Active cancer
  • Unstable angina
  • Recent stroke
  • Current therapy that may affect glucose metabolism such as glucocorticoids, HIV medications, etc
  • Active infection
  • Kidney failure
  • Severe liver dysfunction
  • Severe respiratory or cardiac failure
  • History of allergic reaction to exendin 9-39
  • History of pancreatitis, history of cholelithiasis, history of alcoholism
  • Presence of high triglyceride levels (>600 ng/dl)
  • Pregnancy (a pregnancy test will be done prior to enrollment and prior to each procedure in all premenopausal women)

Treatment and study plan

Exendin9

Drug

Dosed at 600 pmol/kg/min for 210 minutes.

Other names: Exendin(9-39)

Primary outcomes

  1. Beta Cell Sensitivity (BCS)

    Time frame: at 2 years post GBP surgery

    Oral glucose tolerance test (OGTT) will be used to calculate BCS Graded glucose infusion with arginine (GGI) will be used to calculate BCS

Secondary outcomes

  1. Insulin Secretion Rate (ISR) after OGTT

    Time frame: 2 years post GBP surgery

    An oral glucose tolerance test (OGTT) will be used to estimate ISR in subjects before and up to 2 years after GBP

  2. Insulin Secretion Rate (ISR) after GGI

    Time frame: 2 years post GBP surgery

    A graded glucose infusion with arginine (GGI) will be used to estimate ISR in subjects before and up to 2 years after GBP

  3. Maximal Beta Cell Function

    Time frame: 2 years post GBP surgery

    The effect of a graded glucose infusion with arginine (GGI) on insulin secretion rate (ISR) will be measured in subjects before and up to 2 years after GBP

Sponsors and collaborators

Lead sponsor

Blandine Laferrere

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Institutes of Health (NIH)

Registry information

Official study title

Long Term Change of GLP-1 Insulinotropic Effect After GBP Surgery

Important dates

Study start
2014
Primary completion
2017
Study completion
2019
First posted
Nov 10, 2014
Registry last updated
Apr 24, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.